Research Topics
Species | Peter I TernessSummaryAffiliation: University of Heidelberg Country: Germany Publications
| Collaborators
|
Detail Information
Publications
The T-cell suppressive effect of bufadienolides: structural requirements for their immunoregulatory activityP Terness
Institute of Immunology, Department of Transplantation Immunology, INF 305, University of Heidelberg, 69120 Heidelberg, Germany
Int Immunopharmacol 1:119-34. 2001..A similar bufadienolide occurs naturally in mammals. We speculate that bufadienolides represent an important bioregulatory link between the cardiovascular, nervous and immune systems...- Immunosuppressive anti-immunoglobulin autoantibodies: specificity, gene structure and function in health and diseasePeter I Terness
Institute of Immunology, University of Heidelberg, Germany
Cell Mol Biol (Noisy-le-grand) 48:271-8. 2002..There is substantial evidence indicating that anti-Ig auto-Abs are important immunoregulatory molecules... 
Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolitesPeter Terness
Institute of Immunology, Department of Transplantation Immunology, University of Heidelberg, 69120 Heidelberg, Germany
J Exp Med 196:447-57. 2002....- Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivoThomas M Bauer
Department of Transplantation Immunology, Institute of Immunology, University of Heidelberg, 69120 Heidelberg, Germany
Transpl Int 18:95-100. 2005..The metabolites induced a significant prolongation (P = 0.0018) of graft survival. We conclude that IDO-induced tryptophan metabolites suppress the T-cell response and prolong allograft survival in rats... 
Mitomycin C-treated antigen-presenting cells as a tool for control of allograft rejection and autoimmunity: from bench to bedsidePeter Terness
Institute of Immunology, University of Heidelberg, Department of Transplantation Immunology, Heidelberg, Germany
Hum Immunol 70:506-12. 2009..Although many questions remain, MMC-treated cells are a promising clinical tool for controlling allograft rejection and deleterious immune responses in autoimmune diseases...- Mitomycin C-treated dendritic cells inactivate autoreactive T cells: toward the development of a tolerogenic vaccine in autoimmune diseasesPeter Terness
Institute of Immunology, Department of Transplantation Immunology, University of Heidelberg, Im Neuenheimer Feld 305, D 69120 Heidelberg, Germany
Proc Natl Acad Sci U S A 105:18442-7. 2008.... - Suppressive dendritic cells as a tool for controlling allograft rejection in organ transplantation: promises and difficultiesSandra Ehser
Institute of Immunology, University of Heidelberg, Heidelberg, Germany
Hum Immunol 69:165-73. 2008..Based on lessons learned from the use of DCs as tools in clinical vaccine trials in cancer, we discuss the unknown aspects and risks of DC therapy in transplantation... - Inhibition of heart allograft rejection with mitomycin C-treated donor dendritic cellsLucian P Jiga
Institute of Immunology, Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany
Transplantation 83:347-50. 2007..We conclude that allogeneic MMC-DCs specifically inhibit the T-cell response in vivo and that downregulation of CD80, CD86, and ICAM-1 is a potential mechanism of this effect... - Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipientsGerhard Opelz
Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany
Transplantation 81:1227-33. 2006..It is widely assumed that the graft-enhancing properties of antilymphocyte induction agents and their lymphoma-inducing potential are intimately related... - The immunoregulatory role of IDO-producing human dendritic cells revisitedPeter Terness
Institute of Immunology, Department of Transplantation Immunology, INF 305, University of Heidelberg, 69120 Heidelberg, Germany
Trends Immunol 27:68-73. 2006..Here, we critically examine the arguments for and against a function of IDO-expressing human dendritic cells (DCs) and conclude that proof for an immunoregulatory role in vivo is still lacking... - Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO?Peter Terness
Institute of Immunology, University of Heidelberg, INF 305, 69120 Heidelberg, Germany
Blood 105:2480-6. 2005..Our findings show that nonadherent CD123+/CCR6+ human DCs do not constitutively express IDO, and, even if they express the enzyme after IFN-gamma treatment, they possess only limited T-cell regulatory function... - Generation of tolerogenic dendritic cells by treatment with mitomycin C: inhibition of allogeneic T-cell response is mediated by downregulation of ICAM-1, CD80, and CD86Lucian P Jiga
Department of Transplantation Immunology, Heidelberg, Germany
Transplantation 77:1761-4. 2004..CONCLUSIONS: MMC treatment converts rat DC into tolerogenic cells. This mechanism is mediated by decrease of ICAM-1, CD80, and CD86... - Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myelomaMichael Hundemer
Department of Internal Medicine V, University of Heidelberg, Germany
Exp Hematol 34:486-96. 2006..Specifically activated CD8(+) T cells are able to lyse MM cell lines. We conclude that HM1.24 aa22-30 represents a suitable candidate target for a specific peptide-based immunotherapy of MM... - Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivativesDinara Daniel
Department of Transplantation Immunology, Institute of Immunology, University of Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany
Int Immunopharmacol 3:1791-801. 2003..The description of compounds without cardiac activity but with tumor-specific cytotoxicity suggests the potential of using them in cancer therapy... - Comparison of six methods for the assessment of ischemia-reperfusion injury in skeletal muscle following composite tissue allotransplantationSteffen P Baumeister
Department of Hand, Plastic, and Reconstructive Surgery, Burn Center, BG Trauma Center, Ludwigshafen, University of Heidelberg, Germany
J Reconstr Microsurg 20:253-9. 2004..These findings help further researchers in their selection of reliable outcome parameters to measure I/R injury in skeletal muscle... - Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myelomaSebastian Belle
Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
Eur J Haematol 81:26-35. 2008..The aim of this study is the identification of HLA-A2 restricted T-cell epitopes in the conserved region of the immunoglobulin-G-heavy-chain (IgGH) that can be used for immunotherapy in multiple myeloma (MM) patients... - Tolerance signaling molecules and pregnancy: IDO, galectins, and the renaissance of regulatory T cellsPeter Terness
Institute of Immunology, University of Heidelberg, Heidelberg, Germany
Am J Reprod Immunol 58:238-54. 2007..Is the concept of maternal tolerance preventing rejection of the semi-allogeneic 'fetal allograft' still valid?.. - Ex vivo perfusion with mitomycin C containing solution prolongs heart graft survival in ratsDaohu Wang
Institute for Immunology, Department of Transplantation Immunology, University of Heidelberg, Heidelberg, Germany
Transplantation 82:1537-40. 2006..Our findings indicate that the targeted perfusion of donor hearts with MMC-containing solution protects the graft from rejection... - A simplified technique for heart transplantation in rats: abdominal vessel branch-sparing and modified venotomyDaohu Wang
Institute of Immunology, Department of Transplantation Immunology, University of Heidelberg, 69120 Heidelberg, Germany
Microsurgery 26:470-2. 2006.... - Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24Olaf Christensen
Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
J Immunother 32:613-21. 2009..The current data demonstrate that Melan-A analog specific T-cells crossreact with HM1.24(aa22-30). They might be a tool for the future use in immunotherapy against MM...